Therefore, inhibiting tumor cell αv integrin (or its downstream TGF-β signaling) holds promise for enhancing anti-PD-1 therapy efficacy by enabling more cytotoxic T cells to infiltrate tumors and exert their effects. The gene discussed is TGFB1; the disease is neoplasm.